厄贝沙坦/氢氯噻嗪治疗轻中度原发性高血压疗效观察

Clinical observation of Irbesartan/Hydrochlorothiazide tablets in the treatment of mild and moderate essential hypertension

目的评价厄贝沙坦/氢氯噻嗪复方片剂(依伦平)治疗轻、中度原发性高血压的临床疗效和不良反应。方法 52例轻、中度原发性高血压患者均服用依伦平8周,分别观测服药后1、4、8周的血压及用药前后生化指标的变化。结果较治疗前血压明显下降(P<0·01);降压的总效率为90·2%;舒张压<85mmHg的达标率为80·8%;血生化指标无明显变化,未观察到严重不良反应。结论厄贝沙坦/氢氯噻嗪复方片剂(依伦平)治疗轻、中度原发性高血压安全、有效,无明显不良反应。

Objective To assess the clinical effect and untoward effect of Irbesartan/Hydrochlorothiazide tablets in the treatment of the mild and moderate essential hypertension.Methods 52 cases of the essential hypertension were taked Irbesartan/Hydrochlorothiazide tablets,course of 8 weeks.The changes of blood pressure after1、4、8 weeks and blood biochemical indicators were observed before and after treatment.Results Blood pressure decreased significantlyaftertreatmentcompared with before treatment（P0·01）.The total efficacy rate was 90·2%;And the control rate was 80·8%（diastolic blood pressure less than 85 mm Hg）.There were no obvious changes of blood biochemical indicators（P0·05） and rare serious untoward effect.Conclusion Irbesartan/Hydrochlorothiazide tablets is a safe,effective drug for the mild and moderate essential hypertension with rare untoward effect.